Project Grant R01HL187595
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $516K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $796,500 project grant to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to investigate clonal evolution in Fanconi anemia. The grant period runs from September 30, 2023 to September 29, 2026. As a non-profit pediatric teaching hospital and research center, Boston Children's Hospital will leverage its expertise in pediatric medicine, genomics, and...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital Corporation (doing business as Boston Children's Hospital) $825,533 for Project Grant R01HL182745 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The project investigates glycorna-based control of angiogenesis through heparan sulfate binding growth factors. Research focuses on how vascular endothelial growth factor (VEGF-A) orchestrates vascular and cardiac development by binding...
- The National Heart, Lung, and Blood Institute (NHLBI) of the Department of Health and Human Services awarded The Leland Stanford Junior University $1,324,006 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop innovative cell and gene therapy strategies to treat Fanconi anemia. The award funds research to establish functional hematopoietic stem and progenitor cells (HSPCs) in bone marrow that can maintain hematopoiesis without genotoxic chemotherapy...
- The federal Project Grant award in the amount of $617,367 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award is being used by the Children's Hospital Corporation, doing business as Boston Children's Hospital, to conduct research on "BASE EDITING TO IMPROVE CONDITIONING AND TRANSPLANT OF BONE MARROW FAILURE PATIENTS". The research project aims to leverage innovative gene editing techniques to enhance the...
- The National Heart, Lung, and Blood Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded $1,733,846 to The Children's Hospital Corporation, doing business as Boston Children's Hospital, on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate emperipolesis as a driver of platelet heterogeneity and function. The award funds basic science research examining how neutrophils interact with megakaryocytes...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital Corporation, doing business as Boston Children's Hospital, $857,878 for a Project Grant (R01HL188153) on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds development and evaluation of pediatric cardiac foundation models—machine learning models pre-trained on large volumes of unlabeled electrocardiogram (ECG), echocardiogram (ECHO), chest X-ray, and clinical text...
- Federal Grant Award Summary Boston Children's Hospital received a $267,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, with completion anticipated by July 31, 2027. The award funds research to identify shared molecular mechanisms underlying congenital heart disease (CHD) and neurodevelopmental delay and disability (NDD) by characterizing dysregulated gene expression in...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $2,712,905 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop safe, effective, and scalable curative therapies for hemoglobinopathies including sickle cell disease, alpha-thalassemia, beta-thalassemia, and Fanconi anemia by targeting hematopoietic stem cells in vivo using antibody-directed, lipid nanoparticle delivery systems. The research strategy...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Trustees of Boston University $100,228 on December 12, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate enhancement of engraftment potential in human hematopoietic stem cells. The research addresses the challenge of preserving hematopoietic stem cell functionality during the ex vivo culture steps required for gene editing therapies. The project employs multi-modal profiling of...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital Corporation (Boston Children's Hospital) $866,279 on May 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate coordinated protein synthesis and degradation during neonatal heart regeneration. The project addresses mechanistic gaps in understanding how neonatal cardiomyocytes regenerate after ischemic injury—a capacity absent in adult hearts. The research focuses on proteome...